Indeed, the HOPE study was not sufficiently powered or designed to look specifically at diabetic retinopathy. The normotensive group receiving the ACE inhibitor did show a small but significant reduction in diastolic blood pressure, although this was thought to be unlikely to account for these differences in progression of retinopathy.
In summary, the HOPE study demonstrates what appears to be an important role for ACE inhibition in the management of patients at high risk of cardiovascular disease, a benefit which may be obtained over and above their systemic blood pressure lowering effects. In addition, the study provides some support for the possibility that this approach may also be of benefit in diabetic patients not just from the point of view of cardiovascular disease and nephropathy, but also for prevention and treatment of diabetic retinopathy.
Clearly, further studies are required to answer the question as to whether ACE inhibition is an effective approach to the medical management of diabetic retinopathy.
